Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review

Korompoki, Eleni; Gavriatopoulou, Maria; Hicklen, Rachel S; Ntanasis‐Stathopoulos, Ioannis; Kastritis, Efstathios; Fotiou, Despina; Stamatelopoulos, Kimon; Terpos, Evangelos; Κοτανίδου, Αναστασία; Hagberg, Carin A.; Kontoyiannis, Dimitrios P.

doi:10.1016/j.jinf.2021.05.004

Cited by 116 publications

(78 citation statements)

References 178 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The worldwide pandemic declared in March 2020, caused by the spread of the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains an ongoing global health issue [1,2]. COVID-19 is a multisystemic disease with shortand long-term manifestations [3,4]. The clinical spectrum ranges from mild symptoms to a severe and life-threatening disease course in up to 5-10% of patients [3].…”

Section: Introductionmentioning

confidence: 99%

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Terpos

Gavriatopoulou

Fotiou

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutralizing antibodies (NAbs) against SARS-CoV-2 on day 1 of the first vaccine, and afterwards on day 22 and 50. One hundred and thirty-two patients with CLL/lymphomas and 214 healthy matched controls vaccinated during the same period, at the same center were enrolled in the study (NCT04743388). Vaccination with two doses of the BNT162b2 vaccine led to lower production of NAbs against SARS-CoV-2 in patients with CLL/lymphomas compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Disease-related immune dysregulation and therapy-related immunosuppression are involved in the low humoral response. Importantly, active treatment with Rituximab, Bruton’s tyrosine kinase inhibitors, or chemotherapy was an independent prognostic factor for suboptimal antibody response. Patients with HL showed superior humoral responses to the NHL/CLL subgroups. In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures.

show abstract

Section: Introductionmentioning

confidence: 99%

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Terpos

Gavriatopoulou

Fotiou

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The current epidemiology, clinical diagnosis, and treatment of COVID-19 have helped in gathering some experience, which has been used in conducting scientific studies. Some of such studies have suggested that some COVID-19 survivors present with health issues after discharge [ 12 ]. However, the information on long‐term consequences and rehabilitation management of HCWs recovering from COVID‐19 is limited.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan

et al. 2021

View full text Add to dashboard Cite

Introduction To assess the long-term consequences of coronavirus disease (COVID-19) among health care workers (HCWs) in China (hereafter surviving HCWs). Methods A total of 303 surviving HCWs were included. Lung (pulmonary function test, 6-min walk test [6MWT], chest CT), physical (St. George’s Respiratory Questionnaire [SGRQ], Modified Medical Research Council dyspnea scale [mMRC], and Borg scale), and psychiatric functions (Essen Trauma Inventory) were evaluated during the 1-year follow-up. Results Surviving HCWs had an abnormal diffusion capacity 1 year post-discharge. Participants with a reduced carbon monoxide diffusing capacity (DLCO) comprised 43.48%. The proportion of HCWs with a median 6MWT distance below the lower limit of the normal was 19.4%. An abnormal CT pattern was observed in 37.5% of the HCWs. The SGRQ, mMRC, and Borg scores of surviving HCWs, especially those with critical/severe disease, were significantly higher than those in the normal population. Probable post-traumatic stress disorder (PTSD) was reported in 21.9% of the surviving HCWs. Diffusion capacity impairment was associated with women. Critical/severe illness and nurses were associated with impaired physical function. Conclusions Most surviving HCWs, especially female HCWs, still had an abnormal diffusion capacity at 1 year. The physical and psychiatric functions of surviving HCWs were significantly worse than those of the healthy population. Long-term follow-up of pulmonary, physical, and psychiatric functions for surviving HCWs is required. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-021-00553-0.

show abstract

“…The virus penetrates through the viral S protein to the angiotensin-converting enzyme 2 (ACE2) receptors that are mainly presented on oral mucosa epithelial cells and lung alveolar type II cells, as well as in other human tissues [1,2]. COVID-19 is a systemic disease with both short-and long-term manifestations [3,4]. Most of the patients will present with mild or moderate symptoms, although up to 5-10% will present with severe or life-threatening disease course.…”

Section: Introductionmentioning

confidence: 99%

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers

Terpos

Trougakos

Karalis

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

The aim of this study was to investigate the kinetics of neutralizing antibodies (NAbs) and anti-SARS-CoV-2 anti-S-RBD IgGs up to three months after the second vaccination dose with the BNT162b2 mRNA vaccine. NAbs and anti-S-RBD levels were measured on days 1 (before the first vaccine shot), 8, 22 (before the second shot), 36, 50, and three months after the second vaccination (D111) (NCT04743388). 283 health workers were included in this study. NAbs showed a rapid increase from D8 to D36 at a constant rate of about 3% per day and reached a median (SD) of 97.2% (4.7) at D36. From D36 to D50, a slight decrease in NAbs values was detected and it became more prominent between D50 and D111 when the rate of decline was determined at −0.11 per day. The median (SD) NAbs value at D111 was 92.7% (11.8). A similar pattern was also observed for anti-S-RBD antibodies. Anti-S-RBDs showed a steeper increase during D22–D36 and a lower decline rate during D36–D111. Prior COVID-19 infection and younger age were associated with superior antibody responses over time. In conclusion, we found a persistent but declining anti-SARS-CoV-2 humoral immunity at 3 months following full vaccination with BNT162b2 in healthy individuals.

show abstract

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review

Cited by 116 publications

References 178 publications

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers

Contact Info

Product

Resources

About